• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于确定癌症中体细胞遗传事件时间顺序的数学框架。

A mathematical framework to determine the temporal sequence of somatic genetic events in cancer.

机构信息

Computational Biology Center, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

出版信息

Proc Natl Acad Sci U S A. 2010 Oct 12;107(41):17604-9. doi: 10.1073/pnas.1009117107. Epub 2010 Sep 23.

DOI:10.1073/pnas.1009117107
PMID:20864632
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2955151/
Abstract

Human cancer is caused by the accumulation of genetic alterations in cells. Of special importance are changes that occur early during malignant transformation because they may result in oncogene addiction and represent promising targets for therapeutic intervention. Here we describe a computational approach, called Retracing the Evolutionary Steps in Cancer (RESIC), to deduce the temporal sequence of genetic events during tumorigenesis from cross-sectional genomic data of tumors at their fully transformed stage. When applied to a dataset of 70 advanced colorectal cancers, our algorithm accurately predicts the sequence of APC, KRAS, and TP53 mutations previously defined by analyzing tumors at different stages of colon cancer formation. We further validate the method with glioblastoma and leukemia sample data and then apply it to complex integrated genomics databases, finding that high-level EGFR amplification appears to be a late event in primary glioblastomas. RESIC represents the first evolutionary mathematical approach to identify the temporal sequence of mutations driving tumorigenesis and may be useful to guide the validation of candidate genes emerging from cancer genome surveys.

摘要

人类癌症是由细胞中遗传改变的积累引起的。特别重要的是,在恶性转化早期发生的变化,因为它们可能导致癌基因成瘾,并代表治疗干预的有前途的靶点。在这里,我们描述了一种计算方法,称为回溯癌症中的进化步骤(RESIC),该方法从完全转化阶段的肿瘤的横截面基因组数据中推断肿瘤发生过程中的遗传事件的时间顺序。当应用于 70 例高级结直肠癌的数据集时,我们的算法准确预测了先前通过分析结肠癌形成的不同阶段的肿瘤所定义的 APC、KRAS 和 TP53 突变的顺序。我们还使用神经胶质瘤和白血病样本数据进一步验证了该方法,然后将其应用于复杂的综合基因组学数据库,发现高水平的 EGFR 扩增似乎是原发性神经胶质瘤中的晚期事件。RESIC 代表了识别驱动肿瘤发生的突变的时间顺序的第一个进化数学方法,它可能有助于指导从癌症基因组调查中出现的候选基因的验证。

相似文献

1
A mathematical framework to determine the temporal sequence of somatic genetic events in cancer.用于确定癌症中体细胞遗传事件时间顺序的数学框架。
Proc Natl Acad Sci U S A. 2010 Oct 12;107(41):17604-9. doi: 10.1073/pnas.1009117107. Epub 2010 Sep 23.
2
A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis.一种用于确定胶质瘤发生过程中途径改变的时间顺序的数学方法。
PLoS Comput Biol. 2012 Jan;8(1):e1002337. doi: 10.1371/journal.pcbi.1002337. Epub 2012 Jan 5.
3
Genetic analysis in APC, KRAS, and TP53 in patients with stomach and colon cancer.胃癌和结肠癌患者的APC、KRAS及TP53基因分析。
Rev Gastroenterol Mex. 2014 Apr-Jun;79(2):79-89. doi: 10.1016/j.rgmx.2014.05.001. Epub 2014 May 24.
4
The presence of telomere fusion in sporadic colon cancer independently of disease stage, TP53/KRAS mutation status, mean telomere length, and telomerase activity.散发性结肠癌中端粒融合的存在与疾病分期、TP53/KRAS突变状态、平均端粒长度及端粒酶活性无关。
Neoplasia. 2014 Oct 23;16(10):814-23. doi: 10.1016/j.neo.2014.08.009. eCollection 2014 Oct.
5
Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).使用低体积活检组织的全基因组扩增(WGA)来评估表皮生长因子受体(EGFR)、 Kirsten 大鼠肉瘤病毒癌基因(KRAS)、p53和间质上皮转化因子(CMET)突变在晚期非小细胞肺癌(NSCLC)中的预后作用。
J Thorac Oncol. 2009 Jan;4(1):12-21. doi: 10.1097/JTO.0b013e3181913e28.
6
The impact of TP53 and RAS mutations on cerebellar glioblastomas.TP53和RAS突变对小脑胶质母细胞瘤的影响。
Exp Mol Pathol. 2014 Oct;97(2):202-7. doi: 10.1016/j.yexmp.2014.07.009. Epub 2014 Jul 16.
7
Oncogenetic tree model of somatic mutations and DNA methylation in colon tumors.结肠肿瘤中体细胞突变和DNA甲基化的肿瘤发生树模型。
Genes Chromosomes Cancer. 2009 Jan;48(1):1-9. doi: 10.1002/gcc.20614.
8
pathTiMEx: Joint Inference of Mutually Exclusive Cancer Pathways and Their Progression Dynamics.PathTiMEx:互斥癌症通路及其进展动力学的联合推断
J Comput Biol. 2017 Jun;24(6):603-615. doi: 10.1089/cmb.2016.0171. Epub 2016 Dec 12.
9
Analysis of mutations in TP53, APC, K-ras, and DCC genes in the non-dysplastic mucosa of patients with inflammatory bowel disease.炎症性肠病患者非发育异常黏膜中TP53、APC、K-ras和DCC基因的突变分析。
Int J Colorectal Dis. 2009 Oct;24(10):1141-8. doi: 10.1007/s00384-009-0748-5. Epub 2009 Jun 20.
10
Integrative approach for prioritizing cancer genes in sporadic colon cancer.整合方法用于对散发性结肠癌中的癌症基因进行优先级排序。
Genes Chromosomes Cancer. 2009 Nov;48(11):953-62. doi: 10.1002/gcc.20697.

引用本文的文献

1
Polyclonality and metabolic heterogeneity in a colorectal tumor model.结直肠癌肿瘤模型中的多克隆性和代谢异质性
iScience. 2025 Jul 10;28(8):113090. doi: 10.1016/j.isci.2025.113090. eCollection 2025 Aug 15.
2
Resolving tumor evolution: a phylogenetic approach.解析肿瘤进化:一种系统发育学方法。
J Natl Cancer Cent. 2024 Mar 21;4(2):97-106. doi: 10.1016/j.jncc.2024.03.001. eCollection 2024 Jun.
3
Frequency-dependent selection of neoantigens fosters tumor immune escape and predicts immunotherapy response.频率相关的新抗原选择促进肿瘤免疫逃逸,并预测免疫治疗反应。
Commun Biol. 2024 Jun 25;7(1):770. doi: 10.1038/s42003-024-06460-7.
4
Computational Methods Summarizing Mutational Patterns in Cancer: Promise and Limitations for Clinical Applications.总结癌症突变模式的计算方法:临床应用的前景与局限
Cancers (Basel). 2023 Mar 24;15(7):1958. doi: 10.3390/cancers15071958.
5
A phylogenetic approach to inferring the order in which mutations arise during cancer progression.一种推断癌症进展过程中突变发生顺序的系统发育方法。
PLoS Comput Biol. 2022 Dec 2;18(12):e1010560. doi: 10.1371/journal.pcbi.1010560. eCollection 2022 Dec.
6
Dissecting and analyzing the Subclonal Mutations Associated with Poor Prognosis in Diffuse Glioma.解析弥漫性神经胶质瘤不良预后相关亚克隆突变。
Biomed Res Int. 2022 Apr 18;2022:4919111. doi: 10.1155/2022/4919111. eCollection 2022.
7
Early Breast Cancer Evolution by Autosomal Broad Copy Number Alterations.常染色体广泛拷贝数改变导致的早期乳腺癌进展
Int J Genomics. 2022 Feb 25;2022:9332922. doi: 10.1155/2022/9332922. eCollection 2022.
8
Conditional prediction of consecutive tumor evolution using cancer progression models: What genotype comes next?基于癌症演进模型的连续肿瘤演进的条件预测:接下来是什么基因型?
PLoS Comput Biol. 2021 Dec 21;17(12):e1009055. doi: 10.1371/journal.pcbi.1009055. eCollection 2021 Dec.
9
Computational Reconstruction of Clonal Hierarchies From Bulk Sequencing Data of Acute Myeloid Leukemia Samples.从急性髓系白血病样本的批量测序数据中进行克隆层次结构的计算重建
Front Physiol. 2021 Aug 23;12:596194. doi: 10.3389/fphys.2021.596194. eCollection 2021.
10
Extreme value theory as a framework for understanding mutation frequency distribution in cancer genomes.极值理论作为理解癌症基因组中突变频率分布的一个框架。
PLoS One. 2021 Aug 23;16(8):e0243595. doi: 10.1371/journal.pone.0243595. eCollection 2021.

本文引用的文献

1
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.转化事件的遗传分析,这些事件将慢性骨髓增殖性肿瘤转化为白血病。
Cancer Res. 2010 Jan 15;70(2):447-52. doi: 10.1158/0008-5472.CAN-09-3783. Epub 2010 Jan 12.
2
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis.神经纤维瘤病1型肿瘤抑制因子在神经胶质瘤发生过程中的蛋白酶体及基因失活作用
Cancer Cell. 2009 Jul 7;16(1):44-54. doi: 10.1016/j.ccr.2009.05.009.
3
Acquired mutations in TET2 are common in myelodysplastic syndromes.TET2基因的获得性突变在骨髓增生异常综合征中很常见。
Nat Genet. 2009 Jul;41(7):838-42. doi: 10.1038/ng.391. Epub 2009 May 31.
4
Mutation in TET2 in myeloid cancers.髓系癌症中TET2基因的突变。
N Engl J Med. 2009 May 28;360(22):2289-301. doi: 10.1056/NEJMoa0810069.
5
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.髓系恶性肿瘤中TET1、TET2和TET3改变的遗传学特征
Blood. 2009 Jul 2;114(1):144-7. doi: 10.1182/blood-2009-03-210039. Epub 2009 May 6.
6
Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.除骨髓增殖性肿瘤外的髓系恶性肿瘤中突变型TET2的检测:慢性粒-单核细胞白血病、骨髓增生异常综合征、骨髓增生异常综合征/骨髓增殖性肿瘤和急性髓系白血病。
Leukemia. 2009 Jul;23(7):1343-5. doi: 10.1038/leu.2009.59. Epub 2009 Mar 19.
7
Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis.致癌性表皮生长因子受体(EGFR)信号传导与肿瘤抑制基因功能丧失在胶质瘤发生过程中相互协作。
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2712-6. doi: 10.1073/pnas.0813314106. Epub 2009 Feb 5.
8
Functional copy-number alterations in cancer.癌症中的功能性拷贝数改变
PLoS One. 2008 Sep 11;3(9):e3179. doi: 10.1371/journal.pone.0003179.
9
Comprehensive genomic characterization defines human glioblastoma genes and core pathways.全面的基因组特征分析确定了人类胶质母细胞瘤的基因和核心通路。
Nature. 2008 Oct 23;455(7216):1061-8. doi: 10.1038/nature07385. Epub 2008 Sep 4.
10
Many faces of Ras activation.Ras激活的多种表现形式。
Biochim Biophys Acta. 2008 Dec;1786(2):178-87. doi: 10.1016/j.bbcan.2008.05.001. Epub 2008 May 21.